CHI Advisors LLC
- SEC CIK
- 0001791468
- Latest filing
- Nov 13, 2023
Holdings in Q4 2022
Holdings as of Dec 31, 2022, filed Feb 13, 2023. Long positions only; changes compare share counts with Q3 2022.
- Positions
- 22
- −3 vs. Q3 2022
- Portfolio value
- $375.4M
- +$3.53M (+0.9%) vs. Q3 2022
| Security | Class | Shares | Value | % of portfolio | Share change | Action | History |
|---|---|---|---|---|---|---|---|
| Direxion Shs ETF Tr25460G716 | DAILY S&P BIOTEC | 25,000 | $431.3K | 0.1% | −25,000−50.0% | Reduced | – |
| ONCROncorus, Inc. | COM | 2,367,436 | $599.7K | 0.2% | 00.0% | Unchanged | History |
| OVIDOvid Therapeutics Inc. | COM | 864,822 | $1.61M | 0.4% | 00.0% | Unchanged | History |
| GTHXG1 Therapeutics, Inc. | COM | 333,945 | $1.81M | 0.5% | +10,000+3.1% | Added | History |
| CRVSCorvus Pharmaceuticals, Inc. | COM | 2,384,402 | $2.03M | 0.5% | 00.0% | Unchanged | History |
| Freeline Therapeutics Hldgs35655L107 | SPONSORED ADS | 4,814,419 | $2.29M | 0.6% | 00.0% | Unchanged | – |
| INZYInozyme Pharma, Inc. | COM | 2,204,876 | $2.32M | 0.6% | +208,599+10.4% | Added | History |
| ORTXOrchard Therapeutics plc | ADS | 7,987,396 | $2.96M | 0.8% | 00.0% | Unchanged | History |
| TSVT2seventy bio, Inc. | COMMON STOCK | 333,252 | $3.12M | 0.8% | −196,971−37.1% | Reduced | History |
| DTILPrecision Biosciences Inc | COM | 3,549,820 | $4.22M | 1.1% | −125,000−3.4% | Reduced | History |
| IMAImageneBio, Inc. | COM | 1,637,372 | $4.36M | 1.2% | +423,068+34.8% | Added | History |
| RLYBRallybio Corp | COM | 726,109 | $4.77M | 1.3% | +531,812+273.7% | Added | History |
| OMGAOmega Therapeutics, Inc. | COMMON STOCK | 1,055,882 | $6.03M | 1.6% | 00.0% | Unchanged | History |
| KROSKeros Therapeutics, Inc. | COM | 215,059 | $10.3M | 2.8% | +14,830+7.4% | Added | History |
| KZRKezar Life Sciences, Inc. | COM | 1,889,451 | $13.3M | 3.5% | +126,658+7.2% | Added | History |
| CMPXCompass Therapeutics, Inc. | COM | 2,829,712 | $14.2M | 3.8% | 00.0% | Unchanged | History |
| LRMRLarimar Therapeutics, Inc. | COM | 3,473,366 | $14.3M | 3.8% | +58,218+1.7% | Added | History |
| CGEMCullinan Therapeutics, Inc. | COM | 3,317,544 | $35.0M | 9.3% | +74,359+2.3% | Added | History |
| RPTXRepare Therapeutics Inc. | COM | 2,800,126 | $41.2M | 11.0% | −269,721−8.8% | Reduced | History |
| Vectivbio Hldg AGH9060V101 | ORD SHS | 5,492,893 | $47.6M | 12.7% | +1,373,321+33.3% | Added | – |
| PLRXPliant Therapeutics, Inc. | COM | 3,169,892 | $61.3M | 16.3% | −239,866−7.0% | Reduced | History |
| RXDXPrometheus Biosciences, Inc. | COM | 923,800 | $101.6M | 27.1% | −677,985−42.3% | Reduced | History |
Options (1)
Puts and calls in the same filing. Amounts are the market value of the underlying shares, which is what 13F reports.
| Security | Class | Puts | Calls |
|---|---|---|---|
| PLRXPliant Therapeutics, Inc. | COM | – | $29.3K |
Sold out since Q3 2022 (3)
Positions held at the end of Q3 2022 that are gone from this filing.